Game-changing technology for real-world patient care

Aventa clinical tests utilize 3D genomics based on Hi-C chemistry within formalin-fixed, paraffin-embedded (FFPE) tumor samples to amplify fusion signal and overcome challenging genomic regions to sequence the genome.

By sequencing linked pairs of reads which occur nearby one another in 3-dimensional and linear space, this technology can detect previously unidentified gene fusions and rearrangements in many different tumor types and detect important variants missed by other clinical testing modalities.

Standard techniques vs Aventa technology

The technical limitations of standard techniques for fusion and rearrangement detection lead to a substantial number of actionable variants being missed:

  • Targeted DNA sequencing (e.g., CGP) — poor sensitivity for fusions and rearrangements

  • RNA sequencing — detects only expressed gene fusions, missing all other rearrangements; RNA is also not stable

  • Fluorescent in situ hybridization (FISH) — low resolution, need to anticipate targets, limited to a few targets

The technology used in Aventa clinical tests overcomes the limitations of standard techniques and:

  • Generates 100-1000 times higher signal compared to RNA or DNA sequencing or FISH, resulting in superior sensitivity

  • Detects variants regardless of where breakpoints occur or the identity of the individual fusion partners

  • Is robust against sample quality issues seen with other assays